Floatz logo

849 assets in Breast Cancer

Therapeutic assets addressing Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Pirfenidone
Breast Cancer
Harbin Medical UniversityP1/2CC (40)
Polo-Like Kinase 1 Inhibitor Nms-1286937
Breast Cancer
Antonio Giordano, MDP1/2CC (40)
Pumitamig
Breast Cancer
Bristol-Myers SquibbP1/2CC (40)
Puxitatug Samrotecan
Breast Cancer
AstraZenecaP1/2CC (40)
Rezatapopt
Breast Cancer
PMV Pharmaceuticals, IncP1/2CC (40)
Shr-A1811 For
Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.P1/2CC (40)
SL-28
Breast Cancer
Second Life TherapeuticsP1/2CC (40)
Solifenacin
Breast Cancer
University of ArkansasP2CC (40)
Solnerstotug
Breast Cancer
Sensei Biotherapeutics, Inc.P1/2CC (40)
st101
Breast Cancer
Sapience TherapeuticsP1/2CC (40)
syh2051
Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.P1/2CC (40)
Tak-500
Breast Cancer
TakedaP1/2CC (40)
Telmisartan
Breast Cancer
Tanta UniversityP1/2CC (40)
Ter-2013
Breast Cancer
Terremoto Biosciences Inc.P1/2CC (40)
Tersolisib
Breast Cancer
Eli Lilly and CompanyP1/2CC (40)
tng348
Breast Cancer
Tango Therapeutics, Inc.P1/2CC (40)
TQB3912
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P1/2CC (40)
Tuvusertib
Breast Cancer
Institut Paoli-CalmettesP1/2CC (40)
Vio-01
Breast Cancer
Valerio TherapeuticsP1/2CC (40)
Vofatamab
Breast Cancer
Fusion Pharmaceuticals Inc.P1/2CC (40)
XS-02
Breast Cancer
NovaOnco Therapeutics Co., Ltd.P1/2CC (40)
[177lu]lu-aby-271
Breast Cancer
AffibodyP1C (39)
18f-αvβ6-bp
Breast Cancer
Julie L. Sutcliffe, Ph.DEarly P1C (39)
5P12-RANTES
Breast Cancer
Orion Biotechnology Polska Sp. z o.o.P1C (39)
[68Ga]Ga-ABY-025
Breast Cancer
Vanderbilt-Ingram Cancer CenterEarly P1C (39)
[68ga]ga-oncofap administration
Breast Cancer
Philogen S.p.A.P1C (39)
art4215
Breast Cancer
Artios Pharma LtdP1C (39)
Axitinib
Breast Cancer
Lynkcell EuropeP1C (39)
Azenosertib
Breast Cancer
Filipa Lynce, MDP1C (39)
Bbo-10203
Breast Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)P1C (39)
Bgb-21447
Breast Cancer
BeOne MedicinesP1C (39)
Bgb-43395
Breast Cancer
BeOne MedicinesP1C (39)
Bms-986500
Breast Cancer
Bristol-Myers SquibbP1C (39)
Btx-A51
Breast Cancer
Edgewood Oncology Inc.P1C (39)
Cnsi-Fe
Breast Cancer
Sichuan Enray Pharmaceutical Sciences CompanyP1C (39)
dm5167
Breast Cancer
DIGMBIOP1C (39)
Epigallocatechin-3-Gallate
Breast Cancer
Ministry of Health, Saudi ArabiaEarly P1C (39)
Erx-315
Breast Cancer
EtiraRx Australia Pty LtdP1C (39)
Flavone, 3,3',4',5,7-Pentahydroxy-
Breast Cancer
Ministry of Health, Saudi ArabiaEarly P1C (39)
Fluoromisonidazole
Breast Cancer
National Cancer Institute (NCI)P2C (39)
Herclon
Breast Cancer
Incepta Pharmaceuticals LtdP1C (39)
Hld-0117
Breast Cancer
Halda Therapeutics OpCo, Inc.P1C (39)
hs-10502
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P1C (39)
hs-20089
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P1C (39)
hs-20093
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P1C (39)
Humnc2-Car22 Car T Cells
Breast Cancer
Minerva Biotechnologies CorporationP1C (39)
Humnc2-Car44 Car T Cells
Breast Cancer
Minerva Biotechnologies CorporationP1C (39)
Immunoglobulin G1 [351-Alanine,386-Alanine,387-Alanine] Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Imm2902 ?1-Chain), Disulfide With 1-125-Signal Regulatory Protein ? [80-Alanine] (Human Isoform 4 Variant) Fusion Protein With Peptide Linker ((Ggggs)3) Fusion Protein With Human-Mus Musculus Monoclonal Imm2902 ?-Chain, Dimer
Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.P1C (39)
IPH5301
Breast Cancer
Institut Paoli-CalmettesP1C (39)
Iso-1 F-18
Breast Cancer
University of PennsylvaniaP1C (39)
Showing 601 to 650 of 849 assets
PreviousPage 13 of 17Next